Fiche publication
Date publication
octobre 2018
Journal
Trials
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALI-YOUCEF Nassim
,
Pr DUCLOUX Didier
,
Pr ROSSIGNOL Patrick
Tous les auteurs :
Girerd S, Frimat L, Ducloux D, Le Meur Y, Mariat C, Moulin B, Mousson C, Rieu P, Dali-Youcef N, Merckle L, Lepage X, Rossignol P, Girerd N, Jaisser F
Lien Pubmed
Résumé
Despite advances in immunosuppressive therapy, kidney graft survival has failed to improve during the last decades. Ischemia/reperfusion injury (IRI) is one of the main pathophysiological mechanisms underlying delayed graft function, which is associated with poor long-term graft survival. Due to organ shortage, the proportion of grafts from expanded criteria donors (ECDs) is ever growing. These grafts may particularly benefit from IRI prevention. In preclinical models, mineralocorticoid receptor antagonists (MRAs) have been shown to efficiently prevent IRI. This study aims to assess the effect of MRA administration in the early phase of kidney transplantation (KT) among recipients of ECD grafts on mid-term graft function.
Mots clés
Expanded criteria donor, Ischemia/reperfusion lesions, Kidney transplantation, Mineralocorticoid receptor antagonist, Randomized controlled trial
Référence
Trials. 2018 Oct 30;19(1):595
